Marshall Urist is VP at Royalty Pharma plc (RPRX). They have made 7 open-market trades across 1 company since 2021, most recently 2026-10-05.
CIK 0001838139
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 4,126 | $252K |
Shares reported on the most recent Form 4, priced at the 2026-09-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPRX | SELL · 10b5-1 | 2026-10-05 | 2026-10-05 | $57.10 | $236K | +5.2% | — | — |
| RPRX | SELL · 10b5-1 | 2026-09-28 | 2026-09-30 | $57.88 | $239K | -0.8% | — | — |
| RPRX | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $55.88 | $508K | -2.7% | -1.2% | +0.9% |
| RPRX | SELL · 10b5-1 | 2026-06-24 | 2026-06-25 | $55.18 | $502K | +6.5% | +7.1% | +5.2% |
| RPRX | SELL · 10b5-1 | 2026-05-20 | 2026-05-21 | $52.75 | $722K | +2.2% | -0.5% | +14.7% |
| RPRX | SELL · 10b5-1 | 2026-05-14 | 2026-05-15 | $53.06 | $726K | +2.4% | +2.0% | +10.2% |
| RPRX | SELL · 10b5-1 | 2026-01-30 | 2026-02-02 | $41.09 | $822K | +5.9% | +12.1% | +18.6% |
| RPRX | SELL · 10b5-1 | 2026-01-23 | 2026-01-26 | $40.26 | $805K | +8.9% | +11.5% | +22.6% |
| RPRX | SELL · 10b5-1 | 2026-01-16 | 2026-01-20 | $39.52 | $790K | +6.3% | +15.1% | +25.8% |
| RPRX | SELL · 10b5-1 | 2026-01-09 | 2026-01-13 | $40.78 | $816K | +0.0% | +10.8% | +19.7% |
| RPRX | SELL · 10b5-1 | 2026-01-02 | 2026-01-06 | $38.48 | $770K | -2.7% | +8.5% | +16.4% |
| RPRX | SELL · 10b5-1 | 2025-12-26 | 2025-12-29 | $39.32 | $786K | +2.9% | +3.5% | +18.8% |
| RPRX | SELL · 10b5-1 | 2025-12-19 | 2025-12-22 | $38.38 | $768K | +2.1% | +2.3% | +17.4% |
| RPRX | SELL · 10b5-1 | 2025-12-16 | 2025-12-17 | $38.32 | $766K | +1.8% | +3.2% | +20.4% |
| RPRX | SELL · 10b5-1 | 2025-12-05 | 2025-12-09 | $39.15 | $3.3M | +0.9% | +5.3% | +19.8% |
| RPRX | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $39.92 | $3.3M | -2.5% | -1.6% | +20.2% |
| RPRX | SELL | 2023-02-22 | 2023-02-24 | $37.30 | $1.7M | -6.0% | +2.3% | -11.8% |
| RPRX | SELL | 2022-07-25 | 2022-07-27 | $43.19 | $1.9M | -1.0% | -1.1% | -4.9% |
| RPRX | SELL | 2022-06-24 | 2022-06-24 | $43.19 | $2.0M | +0.1% | -0.1% | -4.5% |
| RPRX | SELL | 2022-05-16 | 2022-05-16 | $39.85 | $1.9M | -0.6% | -4.3% | +9.1% |
| RPRX | SELL | 2021-06-04 | 2021-06-08 | $46.08 | $3.1M | -5.4% | -11.1% | -16.2% |
| RPRX | SELL | 2021-06-02 | 2021-06-04 | $41.52 | $1.2M | -4.3% | -8.7% | -13.7% |
| RPRX | SELL | 2021-05-20 | 2021-05-24 | $41.08 | $82K | +11.5% | +4.0% | -4.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.